Elevated levels of GLS1 and ASCT2 (SLC1A5) were also observed in resistant cells (Figure S1E,F, Supporting Information), with overexpression of these proteins linked to a higher mortality risk among lung cancer patients (Figure S1G, Supporting Information). Here, GLS is linked to lung carcinoma.